Effects of apolipoprotein A5 haplotypes on the ratio of triglyceride to high-density lipoprotein cholesterol and the risk for metabolic syndrome in Koreans

Table 3 Association of haplotypes in APOA5 and ZNF259 gene regions with metabolic syndrome (MS) risk

Subject	Hap 1 & 2	Subgroup*	11/12/22 [n (%)]	OR (95% CI)^†	P ^†
All	ht1, ht2	Control	988 (61.3)/558 (34.6)/66 (4.09)	1
		Case	410 (55.5)/280 (37.9)/49 (6.63)	1.33 (1.13 - 1.57)	0.000529
	ht1, ht3	Control	988 (80.8)/229 (18.7)/6 (0.491)	1
		Case	410 (77.1)/111 (20.9)/11 (2.07)	1.41 (1.09 - 1.82)	0.00906
	ht2, ht3	Control	66 (45.5)/73 (50.3)/6 (4.14)	1
		Case	49 (44.5)/50 (45.5)/11 (10.0)	1.31 (0.799 - 2.17)	0.285
Men	ht1, ht2	Control	336 (58.9)/215 (37.7)/19 (3.33)	1
		Case	146 (52.3)/110 (39.4)/23 (8.24)	1.50 (1.16 - 1.94)	0.00197
	ht1, ht3	Control	336 (80.2)/81 (19.3)/2 (0.477)	1
		Case	146 (76.0)/43 (22.4)/3 (1.56)	1.43 (0.950 - 2.14)	0.0842
	ht2, ht3	Control	19 (34.5)/34 (61.8)/2 (3.64)	1
		Case	23 (50.0)/20 (43.5)/3 (6.52)	0.766 (0.356 - 1.63)	0.489
Women	ht1, ht2	Control	652 (62.6)/343 (32.9)/47 (4.51)	1
		Case	264 (57.4)/170 (37.0)/26 (5.65)	1.21 (0.976 - 1.50)	0.0813
	ht1, ht3	Control	652 (81.1)/148 (18.4)/4 (0.498)	1
		Case	264 (77.6)/68 (20.0)/8 (2.35)	1.41 (1.00 - 1.97)	0.0463
	ht2, ht3	Control	47 (52.2)/39 (43.3)/4 (4.44)	1
		Case	26 (40.6)/30 (46.9)/8 (12.5)	2.67 (1.25 - 6.07)	0.0142

*Control: subjects with <3 MS risk factors ((1) abdominal obesity with waist circumference ≥ 90 cm for men and ≥ 80 cm for women, (2) systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, or medication for hypertension, (3) TG ≥ 150 mg/dL, (4) HDL-C < 40 mg/dL for men and < 50 mg/dL for women, and (5) fasting blood glucose ≥ 110 mg/dL or medication for hyperglycemia); case: subjects with ≥3 MS risk factors.
^†The odds ratio (OR), 95% confidence interval (CI), and p-value for Hap 2 versus Hap 1 were estimated by logistic regression, after adjusting for age, sex (in all subjects), physical activity (three categories), daily food intake (three categories), clinical history, and medications for hypertension, dyslipidemia, and/or diabetes.

ISSN: 1476-511X